Caribou Biosciences, Inc.
CRBU
$1.85
-$0.07-3.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 89.74% | 8.60% | -23.01% | -3.13% | -41.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 89.74% | 8.60% | -23.01% | -3.13% | -41.62% |
| Cost of Revenue | -21.83% | -26.36% | -34.90% | 7.79% | -2.61% |
| Gross Profit | 29.99% | 28.86% | -6.87% | -24.88% | -2.40% |
| SG&A Expenses | -18.20% | -6.54% | -9.42% | -33.52% | 7.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.90% | -21.52% | -18.89% | -6.54% | -0.12% |
| Operating Income | 26.81% | 23.11% | 18.56% | 6.71% | -3.83% |
| Income Before Tax | 23.83% | 20.57% | -43.51% | 3.01% | -3.46% |
| Income Tax Expenses | -6,011.11% | -- | -- | -- | -104.66% |
| Earnings from Continuing Operations | 25.36% | 20.57% | -43.51% | 3.01% | -2.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.36% | 20.57% | -43.51% | 3.01% | -2.85% |
| EBIT | 26.81% | 23.11% | 18.56% | 6.71% | -3.83% |
| EBITDA | 26.32% | 22.37% | 19.66% | 7.82% | -2.69% |
| EPS Basic | 28.02% | 22.98% | -39.35% | 6.54% | 0.23% |
| Normalized Basic EPS | 26.54% | 22.95% | -8.05% | 6.55% | -0.37% |
| EPS Diluted | 28.02% | 22.98% | -39.35% | 6.54% | 0.23% |
| Normalized Diluted EPS | 26.54% | 22.95% | -8.05% | 6.55% | -0.37% |
| Average Basic Shares Outstanding | 3.70% | 3.14% | 2.98% | 3.78% | 3.09% |
| Average Diluted Shares Outstanding | 3.70% | 3.14% | 2.98% | 3.78% | 3.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |